Glucose Monitoring in OSA (GlucoMOSA)

  • Research type

    Research Study

  • Full title

    Continuous Glucose Monitoring in OSA; A Randomised Continuous Positive Airway Pressure Withdrawal Trial

  • IRAS ID

    298699

  • Contact name

    Christopher Turnbull

  • Contact email

    christopher.turnbull@msd.ox.ac.uk

  • Sponsor organisation

    University of Oxford / Research Governance, Ethics and Assurance

  • ISRCTN Number

    ISRCTN26117790

  • Duration of Study in the UK

    1 years, 11 months, 31 days

  • Research summary

    This study aims to understand the effects of obstructive sleep apnoea (OSA) on blood sugar levels, which cause complications in diabetes.
    Type 2 diabetes mellitus (T2DM) and prediabetes both cause high blood sugar levels. Obstructive sleep apnoea (OSA) is a breathing condition that causes loud snoring and pauses in breathing during sleep. Whilst OSA is linked with high blood sugar levels in patients with T2DM and prediabetes, it is not known whether OSA is the cause of high blood sugar levels in these patients. Continuous positive airway pressure (CPAP) is the main treatment for OSA. CPAP is a snug-fitting face mask that attaches to a machine that blows air to hold the upper airway open and is worn during sleep. One way of proving that OSA effects blood glucose levels is by showing that CPAP treatment improves blood glucose control.
    Participants will be patients with either T2DM or prediabetes, and OSA already on CPAP treatment. We will ask participants to briefly use sham CPAP instead for one week. During this week we will ask participants to wear a continuous glucose monitor, which is patch attached to the forearm or abdomen with a small needle less than the width of a hair. As a comparison, participants will also be asked to wear a continuous glucose monitor for one week with a study CPAP machine which will deliver effective CPAP treatment. The order in which participants receive or effective CPAP treatment will be randomised. We will also collect blood samples before and after both sham and effective CPAP.

    Stopping CPAP is not a major concern as many patients stop their CPAP for 1-2 weeks, such as when they have a cold or when they are on holiday. We conducted a survey of patients with OSA and over 60% of respondents would be willing to consider briefly stopping CPAP for research purposes.
    We aim to see if OSA causes high blood sugar levels. This is an important step to understanding if treating OSA might improve the long-term health of patients with OSA who have diabetes or prediabetes.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    22/LO/0427

  • Date of REC Opinion

    20 Jul 2022

  • REC opinion

    Further Information Favourable Opinion